Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:34 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer
NCT00281021 · University of Louisville · PHASE2 · terminated · last registry update 2018-03-29 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Interim analysis revealed that only 1 patient had a partial response.” | Open Targets' class: insufficient enrollment, negative | Registry record, University of Louisville |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EGFR in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-03-01Results posted on the registry: ETOP IBCSG Partners Foundation, Afatinib (NCT02369484)
- 2019-02-06Phase 3 first posted: AstraZeneca, Durvalumab + (Osimertinib cohort, single-arm, open-label separate cohort) (NCT03833154)
- 2018-11-06Results posted on the registry: AstraZeneca, AZD9291 80 mg/40 mg + placebo + Placebo Erlotinib 150/100mg (NCT02296125)
- 2018-07-24Phase 3 first posted: Takeda, Brigatinib + Alectinib (NCT03596866)
- 2018-05-11Phase 3 first posted: AstraZeneca, Osimertinib 80mg/40mg + Placebo Osimertinib 80mg/40mg (NCT03521154)
- 2017-04-25Results posted on the registry: AstraZeneca, AZD9291 (NCT02442349)
- 2017-04-12Results posted on the registry: Instituto Nacional de Cancerologia de Mexico, Tetracycline (NCT01880515)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision